Liquid biopsy can ‘personalise’ therapy for colon cancer
A randomised trial in Australia shows use of the test reduces adjuvant chemotherapy without increasing cancer recurrence
A liquid biopsy-guided approach to treating stage II colon cancer can reduce reliance on adjuvant chemotherapy without jeopardising patient survival, a pivotal study suggests.
Melbourne-led authors say results from the DYNAMIC trial could further personalise oncological care, with the decision to treat predicated on presence of circulating tumour DNA (ctDNA).
